Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause)

In August 2026, 20,900 of the 19th Stock Acquisition Rights were exercised, and 2,090,000 new shares were delivered. As of the end of the month, 138,700 remained unexercised.

Worth reading
63In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
2090000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)

Who receives how much2,090,000Shares

Number of shares delivered during the month: 2,090,000 new shares

EVO FUND (240,000 rights)

The lower thin line represents the existing number of shares to which these shares will be added.

発行済株式総数

Exercise ratio subject to exercise restrictions: 2.2% (2,090,000 shares / 96,334,098 shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥30.0, ¥31.0, ¥32.0 or ¥33.0. Details of the adjustment clause and adjustment floor: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 240,000 rights. Number exercised during the month: 20,900 rights. Number unexercised as of the end of the month preceding the target month: 159,600 rights. Number unexercised as of the end of the target month: 138,700 rights.
Most recent equity financing
12 June 2026: Issuance of the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause) (see the materials released on 27 May 2026 for details)
Details of issuance or disposal
ItemDetails
Type of issuance or disposal19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 2,090,000 new shares
Intended allotteeEVO FUND (240,000 rights)
Dilution RateExercise ratio subject to exercise restrictions: 2.2% (2,090,000 shares / 96,334,098 shares)
Total number of issued shares104,374,098 shares (as of the end of the month preceding the target month) → Not disclosed
Exercise priceExercise prices during the month: ¥30.0, ¥31.0, ¥32.0 or ¥33.0. Details of the adjustment clause and adjustment floor: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 240,000 rights. Number exercised during the month: 20,900 rights. Number unexercised as of the end of the month preceding the target month: 159,600 rights. Number unexercised as of the end of the target month: 138,700 rights.
Most recent equity financing12 June 2026: Issuance of the 19th Stock Acquisition Rights (with Exercise Price Adjustment Clause) (see the materials released on 27 May 2026 for details)
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status. The reasons for exercising the Stock Acquisition Rights and the use of funds are not stated in this document.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 19th Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Clause) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori